#4649
Claudin 18.2 overexpression in gastric neuroendocrine tumours
Introduction:
Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).
Conference:
Presenting Author:
Gervaso L
Authors:
Gervaso L,
Lobrano R,
Pisa E,
Benini L,
Spada F,
Keywords:
claudin,
gastric NET,
biomarker,
Neuroendocrine tumour,
#3689
Claudin18.2 expression in gastroenteropancreatic neuroendocrine neoplasms – A clinico-pathologic study
Introduction:
Claudin18.2 is a tight junction protein. Currently, the application of Claudin 18.2 antibody in patients has achieved a great efficacy. However, there are still few systematic studies on the expression of Claudin18.2 in gastroenteropancreatic neuroendocrine neoplasms（GEP-NENs).
Conference:
Presenting Author:
Authors:
Sun Y,
Jiang K,
Hu Y,
Li J,
Lu M,
Keywords:
gastroenteropancreatic neuroendocrine neoplasm,
claudin18.2,
expression,
#3575
Claudin 18 immunohistochemistry for determining site of origin of metastatic neuroendocrine tumor
Introduction:
Claudin 18 isoform 2 (CLDN18.2) is selectively expressed in normal and neoplastic gastric tissue and some pancreatic neoplasia. Anti-CLDN18.2 is an investigational therapy in gastric and pancreatic adenocarcinoma and a sensitive and specific immunohistochemical marker in these cancers.
Conference:
Presenting Author:
Smith B
Authors:
Smith B,
Rice K,
Setthavongsack N,
Woltjer R,
Wong M,
Keywords:
neuroendocrine,
immunohistochemistry,
claudin 18,
CLDN18,
gastric,
#2804
Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction:
Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Wong M,
Huynh C,
Kim S,
Dhall D,
Guindi M,
Keywords:
claudin-18,
anti-claudin 18,
neuroendocrine tumor,
neuroendocrine hyperplasia,
autoimmune metaplastic atrophic gastritis,
